Drugs / DA-2811
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04938752 | Jul → Aug 2021 | — | Dong-A ST Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04473417 | Aug 2020 | — | Dong-A ST Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07239440 | Nov 2025 → Dec 2026 expected | type 2 diabetes mellitus | Dong-A ST Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT05743907 | Apr 2023 → Mar 2025 | diabetes mellitus | Dong-A ST Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DA-2811 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05743907 ↗ |
| Route | Oral | “after a single oral dose” NCT04473417 ↗ |